DYAX CORP DYAX (NASDAQ)

(NEW YORK)Shares of Dyax Corp. jumped to a new high Monday on a strong outlook for the company's lead drug candidate DX-88, following the release of study data showing it alleviated symptoms...READ MORE

(CAMBRIDGE, Mass.)Dyax Corp. said Monday that its lead drug candidate DX-88 met its goals in a late-stage clinical trial, reducing symptoms of a genetic blood disorder more effectively than a placeb...READ MORE

(LEXINGTON, Mass.)Biotechnology company Cubist Pharmaceuticals Inc. on Thursday said its second-quarter profit plunged on a licensing deal charge, but adjusted profit soared past Wall Street forecas...READ MORE

(NEW YORK)ViroPharma Inc. shares wavered Wednesday as Wall Street took a second look at the company's buyout of Lev Pharmaceuticals and Lev's drug candidate Cinryze.READ MORE

(NEW YORK)ViroPharma Inc. shares wavered Wednesday as Wall Street took a second look at the company's buyout of Lev Pharmaceuticals and Lev's drug candidate Cinryze.READ MORE

(NEW YORK)A Thomas Weisel analyst upgraded shares of ViroPharma Inc. Wednesday, saying the company has gained a key drug candidate in its buyout of Lev Pharmaceuticals.READ MORE

(NEW YORK)ViroPharma Inc. said Tuesday that it will buy Lev Pharmaceuticals Inc., a biopharmaceutical company that focuses on developing treatments for inflammatory diseases, for up to $617....READ MORE